Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.
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BACKGROUND
Diabetes mellitus is associated with a considerably increased risk of premature atherosclerosis, particularly coronary heart disease (CHD) and peripheral arterial disease [1, 2] . Although more recent analyses have suggested a less marked effect, most authorities consider diabetes to confer at least a twofold excess risk, independently from other conventional risk factors [3, 4] . Even in people without diabetes, fasting blood glucose concentration and glycated hemoglobin (HbA1c) are associated with the risk of vascular disease [3, 5] .
Early studies of cardiovascular mortality in type 1 diabetes suggested that risk only significantly increases after the development of nephropathy, which coincides with a marked deterioration of the lipid profile and blood pressure [6] . In patients with type 1 diabetes and proteinuria a 37-fold excess risk has been described, compared with a relative risk of 4.3 in patients without proteinuria [7] . Importantly this relative risk does not appear to be related to disease duration. More recent analyses have suggested that improved management of other risk factors can reduce the overall relative risk to 3.0 for women and 2.3 for men [8] .
In type 2 diabetes an increased cardiovascular risk often exists for many years before the onset of biochemical hyperglycemia.
During this period obesity and insulin resistance are often present, associated with hypertension and dyslipidemia, usually referred to as metabolic syndrome [9] . These risk factors may lead to the early development of CHD and may account for the increased incidence of diabetes in the period following a diagnosis of cardiovascular disease [10] . In keeping with this observation, about one in six patients with newly diagnosed type 2 diabetes enrolled in the United Kingdom Prospective Diabetes Study (UKPDS; Controlled-Trials.com identifier:
ISRCTN75451837) had evidence of previous silent myocardial infarction [11] .
However, neither the Diabetes Control and Complications Trial (DCCT; ClinicalTrials.gov identifier: NCT00360815) or the UKPDS (apart from 342 patients in the UKPDS metformin subgroup) showed a statistically significant reduction in CHD risk with more intensive glycemic control [12, 13] 
CLINICAL INVESTIGATIONS
The apparently normal serum cholesterol concentrations observed in both type 1 and type 2 diabetes led to the widespread erroneous belief that glycemia alone might explain the observed high CHD rates.
However, the relatively normal cholesterol levels hide an atherogenic lipid profile, with 
DIET AND WEIGHT MANAGEMENT
Lifestyle modifications are the first-line intervention in the management of diabetes dyslipidemia, and include weight loss, dietary modification, and aerobic exercise [36] . Obesity increases insulin resistance and is associated with increased triglycerides and LDL cholesterol and decreased HDL cholesterol [1] . Weight loss is known to be associated with improvements in lipids and other cardiovascular risk factors including the incidence of type 2 diabetes [65, 66] and should therefore be encouraged in overweight patients with diabetes. To achieve sustained weight loss, caloric restriction remains the key and even modest degrees of weight loss are associated with an improvement in glycemic control, HbA1c, and lipid profile [67] .
Increased physical activity may provide some small adjunct to the effect of dietary restriction, but is unlikely to be successful on its own. Reduced fat intake, particularly of saturated fat, should also be encouraged [68] . The American Diabetes Association (ADA) recommends a diet low in trans fat, saturated fat, and cholesterol [69] . In patients without a marked increase in serum triglycerides but who are not obese, some substitution of saturated fat can be made with unrefined carbohydrate foods and some with oleic, linoleic, or omega-3 fish oils [70] . Dietary interventions, while considered first-line treatment for all patients with diabetes, have not been successful in demonstrating a mortality benefit, even with prolonged follow-up [71] .
The gastrointestinal lipase inhibitor orlistat causes fat malabsorption and should be taken close to meals. The patient must adhere to a low fat diet or they will experience steatorrhoea.
There is often early benefit, but then weight loss levels out, likely as the patient learns to omit it if they plan to consume a fatty meal.
Nonetheless any weight loss achieved can improve cardiovascular risk factors [72] .
Orlistat has beneficial effects on serum total and LDL cholesterol levels which are greater than might be explained by weight loss alone [73] . Surgical management of obesity is much more effective than medical treatment [65] . Weight loss after bariatric surgery is also associated with beneficial glycemic effects in diabetes, including achievement of near normal glycemia without medication or reduced medications [74] .
EFFECTS OF HYPOGLYCEMIC AGENTS ON LIPOPROTEINS
Diabetes dyslipidemia can be partly corrected by insulin treatment and improved blood glucose control [75] . Insulin therapy increases HDL cholesterol and reduces circulating triglyceride levels, particularly in patients with poor glycemic control [76] . Metformin decreases serum triglycerides and improves insulin resistance but is often overlooked as a lipid-lowering agent and is generally considered only as a hypoglycemic agent in the management of diabetes [77] . Other drugs used in the management of diabetes may also have unintended positive and negative effects on lipoproteins (see Table 1 ). Of particular interest is the small increase in LDL cholesterol observed following treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors, suggesting that the recently reported significant improvement in cardiovascular outcomes with empagliflozin is unrelated to effects on dyslipidemia [78] . where the mean pretreatment LDL cholesterol was 3.0 mmol/L (\2.5 mmol/L in 25% of patients), the effect of active intervention with for example is a risk factor for CHD even at low levels and its severity is also predictive of future events [105] .
LIPID-LOWERING DRUGS
Most clinical guidelines recommend tight control of dyslipidemia, especially in high risk patients [106, 107] . Importantly, lipid targets are easier to achieve than blood pressure or glycemia targets and target LDL cholesterol levels as low as 1.8 mmol/L are increasingly recommended in patients with established CHD [108, 109] .
A recent position statement from the ADA recommends a screening lipid profile at the time of diagnosis, at age 40 years, and periodically thereafter [110] . Excellence also recently updated its guidance and now advises clinicians to offer statin treatment for primary prevention to adults with type 1 diabetes who are over 40 years, have had diabetes for more than 10 years, or have established nephropathy or other cardiovascular risk factors [113] . These guidelines also recommend statin therapy for primary prevention in type 2 diabetes if the 10-year risk of developing cardiovascular disease is estimated to be greater than 10% using the QRISK2 assessment tool [113] .
In conclusion, statin treatment should effectively be considered for all people with diabetes aged over 40 years or younger if additional cardiovascular risk factors are present, a position recently supported by the Joint British Societies [106] . 
